| Previous Close | 33.620 |
| Open | 33.470 |
| Bid | 33.560 x 8600 |
| Ask | 33.570 x 9800 |
| Day's Range | 33.335 - 33.700 |
| 52 Week Range | 29.830 - 37.390 |
| Volume | 10,501,461 |
| Avg. Volume | 20,637,846 |
| Market Cap | 200.49B |
| Beta | 1.07 |
| PE Ratio (TTM) | 28.28 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.84%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- TheStreet.com•1 hour ago
5 New Breast Cancer Treatments From Lilly, Novartis and Pfizer That Could Double Sales by 2021
In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.
- Investopedia•2 hours ago
Pfizer Downgraded on Patent Expiration for Viagra: Credit Suisse
Analysts downgrade PFE as they suggest that the big pharma stock has limited drivers of upside.
- Benzinga•4 hours ago
Analyst Prescribes Neutral Rating For Pfizer Shares
Previewing second-quarter results of Pfizer Inc. (NYSE: PFE ), Credit Suisse prescribed a Neutral rating for the shares of the company, down from its previous Outperform rating. Pfizer is scheduled to ...
